Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07735546) titled 'A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma' on July 24.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Umoja Biopharma

Condition: Multiple Myeloma in Relapse Multiple Myeloma (MM)

Intervention: Genetic: UB-VV500

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: October 1, 2026

Target Sample Size: 100

To know more, visit https://clinicaltrials.gov/study/NCT07735546

Disclaimer: Curated by HT Syndication....